BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.66 USD
+0.01 (1.87%)
Updated Sep 20, 2024 03:58 PM ET
After-Market: $0.66 0.00 (-0.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BLRX 0.66 +0.01(1.87%)
Will BLRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BLRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BLRX
BioLineRxl launches digital resource for MM patients 'Mobilization Matters'
BioLineRxlLaunches digital resource for MM patients 'Mobilization Matters'
BioLineRx initiated with bullish view at JonesResearch, here's why
BioLineRx Schedules Annual Shareholders Meeting
BLRX Stock Earnings: BioLine Rx Beats Revenue for Q2 2024